通过基于物理的建模和实验验证的实验验证,发现了人类多巴胺载体的新型全抑制剂
Xiaolong Ye1, Shengzhe Deng2, Ding Luo1
1School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, China.
European journal of medicinal chemistry
|December 2, 2025
概括
研究人员发现了一种新的全抑制剂,DAM-001,用于人类多巴胺转运体 (hDAT). 这一发现为开发潜在副作用较少的中枢神经系统疾病治疗方法提供了一种新的策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
背景情况:
- 多巴胺转运体 (DAT) 是治疗中枢神经系统 (CNS) 疾病的关键标.
- 当前的DAT抑制剂作用于orthosteric部位引起副作用,突出需要替代治疗策略.
- 识别DAT上的全位对于设计新型调节器至关重要.
研究的目的:
- 发现人类多巴胺载体 (hDAT) 的新型全调节剂.
- 利用基于hDAT的冷-EM结构的构造导向策略.
- 通过向全位来探索中枢神经系统疾病的新治疗途径.
主要方法:
- 采用hDAT的冷-EM结构的符合性引导策略.
- 虚拟选Enamine图书馆与可使用药物的口袋进行对比.
- 基于光的基质吸收试验.
- 分子动力学 (MD) 模拟和结合自由能分析.
- 监督的MD (SuMD) 来确定绑定途径.
主要成果:
- 鉴定Z236004662 (DAM-001) 作为一种新的hDAT.新型全抑制剂.
- DAM-001显着抑制hDAT活性,与诺米芬辛观察到协同效应.
- 模拟MD阐明了DAM-001.1.的结合机制和协同抑制.
结论:
- 该研究使用基于结构的方法成功确定了hDAT的新型全抑制剂.
- 这项工作验证了一种有前途的战略,用于发现DAT和相关标的全调节剂.
- 这些发现为开发新型治疗中枢神经系统疾病的新疗法铺平了道路,并改善了安全性.
相关概念视频
Allosteric Regulation
62.8K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
62.8K
The Significance of Membrane Transport
40.9K
The transport of solutes across the cell membrane is essential for metabolic processes, like maintaining cell size and volume, generating the action potential, exchanging nutrients and gases, etc. Membrane transport can be either passive or active. It can be simple diffusion, facilitated, or mediated transport aided by transport proteins such as transporters and channels.
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
40.9K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
250
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
250
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Induced-fit Model
88.6K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
88.6K
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
315
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
315


